Kimberly-Clark Corporation (NASDAQ:KMB) rattled its shareholders when it earlier announced its acquisition of consumer goods giant Kenvue Inc (NYSE:KVUE). Ordinarily, such an acquisition might make sense due to the implied expansion of the acquiring entity's product portfolio. However, Kenvue has been ground zero for a controversy involving the flagship over-the-counter medication Tylenol.Looking at the terms of the deal, the cash and stock transaction values Kenvue at an enterprise value of about $48.7 bil ...